Molto A, López-Medina C, Van den Bosch FE, et al. - In axial spondyloarthritis (axSpA), tight control (TC)/treat-to-target (T2T) strategy failed to show significant superiority over usual care (UC) for the primary outcome [percentage of patients with a ≥30% improvement on the ASAS-Health Index (ASAS-HI)], while many secondary efficacy outcomes favored it.

• In this pragmatic, prospective, cluster-randomized, controlled, open, 1-year trial, a total of 160 axSpA patients were included who were assigned to either TC/T2T or to UC.

• Improvement in ASAS-HI by ≥30% was evident in 47.3% of the TC/T2T arm and in 36.1% of those receiving UC (non-significant).

• More frequent occurrence of all secondary efficacy outcomes was evident in the TC/T2T arm, although not all statistically significant.

• Similar safety was observed in both arms.

• From a societal viewpoint, TC/T2T conferred an additional 0.04 quality-adjusted life-years, and saved €472 vs UC.